What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to reaffirm CVS Health's previously issued full-year 2020 financial guidance for GAAP diluted EPS, Adjusted EPS, and cash flow from operations, stating that these remain unchanged despite the COVID-19 pandemic.

Has CVS Health updated its financial guidance due to COVID-19?

For its core guidance metrics (GAAP diluted EPS, Adjusted EPS, and cash flow from operations), CVS Health has reaffirmed its previous targets and not changed them. However, the company had previously withdrawn all other more detailed 2020 guidance due to the significant uncertainty the pandemic creates for other financial line items.

What is 'Adjusted EPS' and how is it calculated?

Adjusted EPS is a non-GAAP measure that CVS Health uses to analyze underlying business performance. It is calculated by taking GAAP net income and excluding items such as amortization of intangible assets and acquisition-related integration costs. The company believes this provides a better view of underlying business trends and allows for easier comparison to prior periods. It is important to note that the company's definition of Adjusted EPS may differ from that of other companies.

What does the reaffirmation of guidance suggest about CVS Health's performance during the pandemic?

The reaffirmation suggests that, as of June 2020, CVS Health's management believed its core business segments were performing in line with expectations and were resilient enough to withstand the impacts of the COVID-19 pandemic without negatively affecting its primary EPS and cash flow projections. However, the withdrawal of other detailed guidance signals awareness of potential volatility in other areas.

CVS 8-K: Regulation FD — Jun 10, 2020

Summary

CVS Health Corporation (CVS) filed an 8-K on June 10, 2020, primarily to reaffirm its previously issued full-year 2020 financial guidance. Despite the ongoing uncertainty of the COVID-19 pandemic, the company stated that its GAAP diluted earnings per share (EPS) guidance remains between $5.47 and $5.60, and its Adjusted EPS guidance is unchanged at $7.04 to $7.17. Furthermore, the company confirmed its full-year 2020 cash flow from operations guidance of $10.5 billion to $11.0 billion is also unchanged. This reaffirmation indicates management's confidence in the company's ability to navigate the pandemic's impacts without altering key financial targets. However, it's important to note that CVS Health had previously withdrawn all other detailed 2020 guidance due to the potential for significant variability across other financial statement line items stemming from the pandemic. The company emphasized that its Adjusted EPS guidance excludes items not reflective of underlying business performance and is provided as a supplemental view.

Key Highlights

1Full-year 2020 GAAP diluted EPS guidance range of $5.47 to $5.60 remains unchanged.
2Full-year 2020 Adjusted EPS guidance range of $7.04 to $7.17 remains unchanged.
3Full-year 2020 cash flow from operations guidance range of $10.5 billion to $11.0 billion remains unchanged.
4All other previously issued detailed 2020 guidance was withdrawn on May 6, 2020, due to COVID-19 uncertainty.
5Company reaffirms guidance despite inherent and unprecedented uncertainty surrounding the COVID-19 pandemic.
6Adjusted EPS guidance excludes items such as amortization of intangible assets and acquisition-related integration costs.
7Guidance is provided in the context of investor meetings scheduled for June 2020.

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Jun 10, 2020)

Summary

Key Highlights

Frequently Asked Questions